Human PerformanceExtremeEndNCT03337737
The Effects of 10 Days of Extreme Endurance on Performance
A study testing Extreme Endurance in people with Human Performance, run by University of Louisiana at Lafayette.
Trial summary
The study will be a double blind, placebo controlled cross over design with equal treatment and washout periods. Participants will sign an informed consent document prior to data collection and will provide descriptive information about their physical activity by filling out the Leisure and Physical Activity Survey. Read more about this study
- Who is it for?
- Ages 18 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Human Performance
- What is being tested?
- Extreme Endurance
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2015to 1 Mar 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Able to participate in vigorous exercise
Who cannot join
- Any exercise contraindication
About this study
Official title: The Effects of 10 Days of Extreme Endurance on Performance, Buffering Capacity During Exercise and Post Exercise Muscle Damage, Oxidative Stress and Inflammation
The study will be a double blind, placebo controlled cross over design with equal treatment and washout periods. Participants will sign an informed consent document prior to data collection and will provide descriptive information about their physical activity by filling out the Leisure and Physical Activity Survey. The participants will be 12 healthy, active college aged males. The participant will have height and weight determined via a triple beam balance with stadiometer, and their body fat% determine via a Bod Pod Gold Standard system.
After wards the participants will supplement with either Placebo or Extreme Endurance (random assignment for order) for ten days. The first 4 days will the participants will ingest four tablets in the morning and evening (8 tablets total) followed by 6 days of three tablets in the morning and evening (6 tablets total). Following the supplementation period the participant will report to the human performance lab where they will be fitted with a mask to collect expired gases and will perform a 25 watt ramp protocol on an electronically braked cycle ergometer. During this test the participant will have a short warm up period, and then a computer will automatically adjust the workload on the bike such that a slope of 25 watts/min is achieved. The test will conclude when the subject reaches volitional exhaustion. Expired gases will be assessed with a COSMED QUARK CPET system. Prior to, and every two minutes during the exercise lactate will be assessed via dermal puncture and a handheld monitor. Ten minutes after the cessation of exercise, a venipuncture will be performed in the antecubetal space and blood will be collected into a serum separator tube. This blood will be spun down in a clinical centrifuge and the serum drawn off and ammonia determined via enzymatic reaction. The remaining serum will be aliquoted and stored at -80 degrees Celsius for later analysis (muscle damage, oxidative stress, inflammation). Participants will then have a ten day rest period after which they will begin the 10 day supplementation period and exercise trial with the opposite supplement.
Read the detailed description
Background and Purpose:
Extreme Endurance has been studied in Europe and the data from these studies suggested that the supplement may reduce acidity and increase exercise performance. The purpose of the present investigation is to assess the total effects of Extreme Endurance during exercise. The investigation will assess the following:
Performance:
Performance will be measured as the peak wattage achieved at the lactate, and ventilator thresholds as well as the peak wattage attained during a 25 watt ramp protocol on a electronically braked cycle ergometer. During this test expired gases will be assessed breath by breath, and lactate will be measured every 2 minutes.
Buffering Capacity:
In the human body decreased inter-muscular pH can be quantified through changes in the amount of expired CO2 and increases in serum ammonia (highly correlated with changes in pH associated with high intensity exercise) and lactate measured in whole blood during the exercise.
Muscle Damage:
Post exercise stress and damage to muscle tissue can be quantified by examining the blood for substances normally contained in the muscle tissue only. For this study both creatine kinase and lactate dehydrogenase will be assessed, both have been used as markers of muscle damage in a plethora of scientific publications.
Oxidative Stress:
During exercise free radicals are generated, which a supplement such as Extreme Endurance can potentially reduce. For this study 8OHdG will be measured, this is a marker of oxidative damage to DNA caused by free radicals produced during exercise.
Inflammation:
Exercise produces a well documented inflammatory response. To examine the effects of Extreme Endurance on inflammation a custom multiplex assay will be run that will measure IL-2, IL-6, TNF alpha and C-reactive protein. These are all common markers for inflammation.
Research Questions:
- Does Extreme Endurance improve performance and increase power output during a graded cycling protocol compared to placebo?
- Does Extreme Endurance improve buffering capacity during a graded cycling protocol compared to placebo?
- Does Extreme Endurance reduce muscle damage caused by a graded cycling protocol compared to placebo?
- Does Extreme Endurance reduce oxidative stress caused by a graded cycling protocol compared to placebo?
- Does Extreme Endurance reduce inflammation caused by a graded cycling protocol compared to placebo?
Methodology
Study Design
The study will be a double blind, placebo controlled cross over design with equal treatment and washout periods. Participants will sign an informed consent document prior to data collection and will provide descriptive information about physical activity history by filling out the Leisure and Physical Activity Survey. The participants will be 16 healthy, active college aged males. The participants will have height and weight determined via a triple beam balance with stadiometer, and body fat% determine via a Bod Pod Gold Standard system.
After wards the participants will supplement with either Placebo or Extreme Endurance (random assignment for order) for ten days. The first 4 days will the participants will ingest four tablets in the morning and evening (8 tablets total) followed by 6 days of three tablets in the morning and evening (6 tablets total). Following the supplementation period the participants will report to the human performance lab where a mask will be fitted to collect expired gases and will perform a 25 watt ramp protocol on an electronically braked cycle ergometer. During this test the participant will have a short warm up period, and then a computer will automatically adjust the workload on the bike such that a slope of 25 watts/min is achieved. The test will conclude when the participant reaches volitional exhaustion. Expired gases will be assessed with a COSMED QUARK CPET system. Prior to, and every two minutes during the exercise lactate will be assessed via dermal puncture and a handheld monitor. Ten minutes after the cessation of exercise, a venipuncture will be performed in the antecubetal space and blood will be collected into a serum separator tube. This blood will be spun down in a clinical centrifuge and the serum drawn off and ammonia determined via enzymatic reaction. The remaining serum will be aliquoted and stored at -80 degrees Celsius for later analysis (muscle damage, oxidative stress, inflammation). Participants will then have a ten day rest period after which they will begin the 10 day supplementation period and exercise trial with the opposite supplement.
Immunoassays
At the conclusion of data collection, serum aliquots will be thawed and analyzed via colormetric or chemiluminescent immunoassays.
Timeframe
Mar 2016 - Begin Subject Recruitment
Sept 2016 - Finish Data collection
- Conditions
- Human Performance
- Being tested
- Extreme Endurance, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Extreme EnduranceDietary supplement
Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.
PlaceboOther
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Placebo will be composed of microcrystalline cellulose in a gel capsule Receives: Other: Placebo |
| Extreme Endurance | Active comparator | Dietary Supplement manufactured by LifeSpan International LLC Receives: Dietary Supplement: Extreme Endurance |
What is being measured
The primary outcome is the main question the study is designed to answer.
Human Performance
Treadmill Exercise
Measured: 10 days
Secondary outcomes (1)
Oxidative Stress
8OHdG assessment
Measured: 10 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2017
- Study start1 Oct 2015
- Primary completion1 Nov 2016
- Study completion1 Mar 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human PerformanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Louisiana at Lafayette
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, David Bellar, University of Louisiana at Lafayette
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03337737
- Sponsor's protocol ID
- FWA00000758
- Acronym
- ExtremeEnd
- Status last verified
- Nov 2017
- First submitted
- 3 Nov 2017
- Last updated
- 9 Nov 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to share IPD with other researchers
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of 10 Days of Extreme Endurance on Performance, Buffering Capacity During Exercise and Post Exercise Muscle Damage, Oxidative Stress and Inflammation
- ClinicalTrials.gov ID
- NCT03337737
- Acronym / sponsor ID
- ExtremeEnd / FWA00000758
- Conditions
- Human Performance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- University of Louisiana at LafayetteUniversity, hospital or other
- Study start
- 1 Oct 2015 (actual)
- Primary completion
- 1 Nov 2016 (actual)
- Study completion
- 1 Mar 2017 (actual)
- First posted
- 9 Nov 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will be a double blind, placebo controlled cross over design with equal treatment and washout periods. Participants will sign an informed consent document prior to data collection and will provide descriptive information about their physical activity by filling out the Leisure and Physical Activity Survey. The participants will be 12 healthy, active college aged males. The participant will have height and weight determined via a triple beam balance with stadiometer, and their body fat% determine via a Bod Pod Gold Standard system.
After wards the participants will supplement with either Placebo or Extreme Endurance (random assignment for order) for ten days. The first 4 days will the participants will ingest four tablets in the morning and evening (8 tablets total) followed by 6 days of three tablets in the morning and evening (6 tablets total). Following the supplementation period the participant will report to the human performance lab where they will be fitted with a mask to collect expired gases and will perform a 25 watt ramp protocol on an electronically braked cycle ergometer. During this test the participant will have a short warm up period, and then a computer will automatically adjust the workload on the bike such that a slope of 25 watts/min is achieved. The test will conclude when the subject reaches volitional exhaustion. Expired gases will be assessed with a COSMED QUARK CPET system. Prior to, and every two minutes during the exercise lactate will be assessed via dermal puncture and a handheld monitor. Ten minutes after the cessation of exercise, a venipuncture will be performed in the antecubetal space and blood will be collected into a serum separator tube. This blood will be spun down in a clinical centrifuge and the serum drawn off and ammonia determined via enzymatic reaction. The remaining serum will be aliquoted and stored at -80 degrees Celsius for later analysis (muscle damage, oxidative stress, inflammation). Participants will then have a ten day rest period after which they will begin the 10 day supplementation period and exercise trial with the opposite supplement.
Detailed description
Background and Purpose:
Extreme Endurance has been studied in Europe and the data from these studies suggested that the supplement may reduce acidity and increase exercise performance. The purpose of the present investigation is to assess the total effects of Extreme Endurance during exercise. The investigation will assess the following:
Performance:
Performance will be measured as the peak wattage achieved at the lactate, and ventilator thresholds as well as the peak wattage attained during a 25 watt ramp protocol on a electronically braked cycle ergometer. During this test expired gases will be assessed breath by breath, and lactate will be measured every 2 minutes.
Buffering Capacity:
In the human body decreased inter-muscular pH can be quantified through changes in the amount of expired CO2 and increases in serum ammonia (highly correlated with changes in pH associated with high intensity exercise) and lactate measured in whole blood during the exercise.
Muscle Damage:
Post exercise stress and damage to muscle tissue can be quantified by examining the blood for substances normally contained in the muscle tissue only. For this study both creatine kinase and lactate dehydrogenase will be assessed, both have been used as markers of muscle damage in a plethora of scientific publications.
Oxidative Stress:
During exercise free radicals are generated, which a supplement such as Extreme Endurance can potentially reduce. For this study 8OHdG will be measured, this is a marker of oxidative damage to DNA caused by free radicals produced during exercise.
Inflammation:
Exercise produces a well documented inflammatory response. To examine the effects of Extreme Endurance on inflammation a custom multiplex assay will be run that will measure IL-2, IL-6, TNF alpha and C-reactive protein. These are all common markers for inflammation.
Research Questions:
- Does Extreme Endurance improve performance and increase power output during a graded cycling protocol compared to placebo?
- Does Extreme Endurance improve buffering capacity during a graded cycling protocol compared to placebo?
- Does Extreme Endurance reduce muscle damage caused by a graded cycling protocol compared to placebo?
- Does Extreme Endurance reduce oxidative stress caused by a graded cycling protocol compared to placebo?
- Does Extreme Endurance reduce inflammation caused by a graded cycling protocol compared to placebo?
Methodology
Study Design
The study will be a double blind, placebo controlled cross over design with equal treatment and washout periods. Participants will sign an informed consent document prior to data collection and will provide descriptive information about physical activity history by filling out the Leisure and Physical Activity Survey. The participants will be 16 healthy, active college aged males. The participants will have height and weight determined via a triple beam balance with stadiometer, and body fat% determine via a Bod Pod Gold Standard system.
After wards the participants will supplement with either Placebo or Extreme Endurance (random assignment for order) for ten days. The first 4 days will the participants will ingest four tablets in the morning and evening (8 tablets total) followed by 6 days of three tablets in the morning and evening (6 tablets total). Following the supplementation period the participants will report to the human performance lab where a mask will be fitted to collect expired gases and will perform a 25 watt ramp protocol on an electronically braked cycle ergometer. During this test the participant will have a short warm up period, and then a computer will automatically adjust the workload on the bike such that a slope of 25 watts/min is achieved. The test will conclude when the participant reaches volitional exhaustion. Expired gases will be assessed with a COSMED QUARK CPET system. Prior to, and every two minutes during the exercise lactate will be assessed via dermal puncture and a handheld monitor. Ten minutes after the cessation of exercise, a venipuncture will be performed in the antecubetal space and blood will be collected into a serum separator tube. This blood will be spun down in a clinical centrifuge and the serum drawn off and ammonia determined via enzymatic reaction. The remaining serum will be aliquoted and stored at -80 degrees Celsius for later analysis (muscle damage, oxidative stress, inflammation). Participants will then have a ten day rest period after which they will begin the 10 day supplementation period and exercise trial with the opposite supplement.
Immunoassays
At the conclusion of data collection, serum aliquots will be thawed and analyzed via colormetric or chemiluminescent immunoassays.
Timeframe
Mar 2016 - Begin Subject Recruitment
Sept 2016 - Finish Data collection
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Other: PlaceboPlacebo will be composed of microcrystalline cellulose in a gel capsule |
| Extreme Endurance | Active comparator | Dietary Supplement: Extreme EnduranceDietary Supplement manufactured by LifeSpan International LLC |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Able to participate in vigorous exercise
Key exclusion criteria (1 listed)
- Any exercise contraindication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Extreme EnduranceStudy will compare (in a crossover) placebo vs dietary supplement Extreme Endurance. | Dietary supplement | Extreme Endurance |
| Placebo | Other | Placebo |
Primary outcome
Human Performance
Time frame: 10 days
Treadmill Exercise
1 secondary outcome
Oxidative Stress
Time frame: 10 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2017.
- Individual participant dataSharing planned: No. There is no plan to share IPD with other researchers
Related trials for Human Performance
Recruiting
Development of a Real-time Controller to Estimate Walking Performance Using a Bilateral Ankle Exoskeleton
Healthy Young Adults
Recruiting
A Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test
HIV1 Infection, HIV 2 Infection
Recruiting
Performance, Feasibility, and Safety Study for a Novel Endoluminal Robotic System for En-Bloc Resection of Bladder Tumours: First-In-Human Trial
Bladder Cancer
Active, not recruitingObservational study
Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diquat Concentrations in Human Blood Samples
Diquat Poisoning
Not yet recruiting
Clinical Study to Evaluate the Performance of the INSTI® HCV Antibody Test for CLIA-Waived Use
HCV Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Extreme Endurance in people with Human Performance, run by University of Louisiana at Lafayette.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Human Performance (time frame: 10 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2017.